Ipamorelin
Synthetic pentapeptide and selective growth-hormone secretagogue (GHS) used in laboratory settings to study GH-related signaling via the GHS-R1a receptor. Unlike broader GHRPs, Ipamorelin is examined for its ability to stimulate GH release with minimal activity at receptors influencing ACTH, cortisol, prolactin, FSH, LH, or TSH in preclinical models. Half-life of ~2 hours and time to peak GH release of ~0.67 hours in preclinical studies. Activates cAMP/PKA signaling, supporting pulsatile GH-release patterns observed in experimental settings.
- Selective GH signaling
- Pulsatile GH dynamics
- Injection-interval modeling
- GH-linked repair models
- Myogenic and metabolic signaling
- Sleep-architecture research
Supplied to verified B2B accounts only — research institutions under RUO, or licensed 503A compounding pharmacies as API. Not FDA-approved for human or veterinary therapeutic use. See the disclaimer.